GSK : presents pivotal data at ESPID confirming effectivenes

Preliminary results from phase III trial show all primary endpoints met, demonstrating statistical non-inferiority compared to Bexsero and Menveo , in individuals 10-25 years old with... | May 12, 2023

Related Keywords

Lisbon , Lisboa , Portugal , United States , Australia , Canada , Czech Republic , Melbourne , Victoria , Estonia , Turkey , Finland , Bexsero Men , Terry Nolan , Bing Wang , Tony Wood , Menveo Men , Immunisation Research Group , University Of Melbourne , Peter Doherty Institute For Infection , National Immunization , National Vaccination Coverage Among Adolescents , Murdoch Children Research Institute , Representative Panel , Annual Meeting , European Society , Paediatric Infectious Diseases , Chief Scientific Officer , Peter Doherty Institute , Murdoch Children , Research Institute , Biologics License Application , Accelerated Approval , Annual Report , Disease Causes , How It Spreads , Based Outbreaks , Meningococcal Disease Caused , Infectious Diseases , Vaccination Coverage Among Adolescents Aged , Immunization Survey Teen , Mortal Wkly Rep , Gsk Plc Stock Exchange , News , Information , Press Release , Reliminary , Results , Rom , Hase , Wii , Trial , Show , Wall , Primary , Endpoints , Emonstrating , Tatistical , Ompared , O , Bexsero , End , Cenveo , N , Individuals , Tears , Ld Gsk Gb00bn7swp63 ,